Arris, Pharmacia & Upjohn deal

The companies agreed to use ARRS's combinatorial chemistry and high throughput screening to create a probe library consisting of 250,000 small molecule synthetic organic compounds for the co-exclusive use of both companies.

ARRS will share with Pharmacia & Upjohn the libraries of newly synthesized compounds and the technologies used for synthesis and screening. Pharmacia & Upjohn will pay undisclosed license fees and milestones. ...